A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)

Merck Sharp & Dohme LLC134 enrolled

Overview

This was a prospective, randomized, controlled, open, and multi-center trial conducted to compare the clinical efficacy and safety of ertapenem with it's comparator before or following adequate surgical management of complicated intra-abdominal infection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

134

Conditions

Complicated Intra-abdominal Infection

Interventions

MK0826; ertapenem sodiumDRUG

Comparator: ceftriaxone + metronidazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females between the ages of 18 and 75 who have complicated intra-abdominal infection.

Outcomes

Primary Outcomes

Favorable clinical response at 7-14 days after treatment

Secondary Outcomes

Favorable microbiologic response at 7-14 days after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.